Naloxone B. Braun (Naloxone Hydrochloride)

Naloxone Hydrochloride works by competitively binding to mu‑opioid receptors without activating them, displacing opioid agonists such as morphine or fentanyl and thereby terminating their analgesic and respiratory‑depressant actions.

The dose of Naloxone B. Braun is determined by the prescribing clinician based on the patient’s condition, the route of administration, and the severity of opioid toxicity. Specific dosing regimens are not provided here.

Safety data for naloxone in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Naloxone is the most widely used opioid antagonist and is available in injectable form for rapid reversal. Alternatives such as nalmefene have a longer half‑life but are less commonly used in emergency settings. The choice depends on clinical context, formulation availability and regulatory approvals.

Naloxone B. Braun should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use.

Naloxone B. Braun is administered by a trained professional via intramuscular or intravenous injection. The route is selected according to the clinical scenario, with intramuscular injection often used in pre‑hospital settings and intravenous injection preferred in hospital environments for faster onset.

Serious risks include severe hypertension, cardiac arrhythmias, pulmonary edema, seizures, and rare anaphylactic reactions. These events are usually related to rapid reversal of opioid effects and should be monitored closely after administration.

Naloxone B. Braun should be avoided in individuals with a known hypersensitivity to naloxone or any of its excipients. It is also contraindicated in patients where reversal of opioid effect could precipitate life‑threatening withdrawal without appropriate medical supervision.